Purpose: Determine the ADAMTS-13 activity in patients with a history of TTP.
ID
Source
Brief title
Condition
- Haematological disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
End point: determination of the ADAMTS-13 activity in blood and the relation
with relapsing TTP.
Secondary outcome
not applicable
Background summary
ADAMTS-13 is involved in the life treatening clottingsdisease TTP. The protein
ADAMTS-13 facilitates the break down of von Willebrand factor. When the
protein is prefented by antibodies to break down the vWF thrombosis can occur.
TTP is treated with plasmaexchange. If TTP is discovered in time it can be
treated well. Recently is discoverd that patients with a history of TTP that
have no ADAMTS-13 activity also have less ADAMTS-13 activity on the long term.
Possibly a small amount of ADAMTS-13 activity is enough to prevent a TTP
episode, though low amounts of ADAMTS-13 activity can cause complaints.
Moreover low amounts of ADAMTS-13 activity is a possible riskfactor for new
relapses of TTP.
Study objective
Purpose: Determine the ADAMTS-13 activity in patients with a history of TTP.
Study design
Study design: Cross-sectional and prospective study
Starting: 01-09-2006, ending: 01-09-2016
50 TTP patients (m/f) with a history of TTP are approached by the TTP patient
association to visit the annual patient day. During this day patients are asked
to fill in a questionnaire and give permission to donate blood for scientific
research (cross-sectional part). Blood will be drawn during this day at the
UMCU. The patient day will be held annually, and every time permission will be
asked for blood withdrawal and filling in the questionnaire (prospective part).
In the future we would like to investigate the relation between relapsing TTP
and the presence or absence of Adamts-13 with this study design .
Study burden and risks
Participation is of hardly any burden. Patients are asked to fill in a
questionnaire on the history and course of their TTP episodes. After consent 10
ml blood is withdrawn by qualified personnel for scienentific research. Risk:
hematoma after venipuncture
Het onderzoek is nauwelijks belastend. De patiënten worden gevraagd een enquete
in te vullen over het verloop en voorgeschiedenis van de TTP aanval. Na het
verkrijgen van toestemming wordt 10 ml bloed afgenomen door gekwalificeerd
personeel voor wetenschappelijk onderzoek. Risico: hematoom na venapunktie.
Heidelberglaan 100
3584 CX Utrecht
Nederland
Heidelberglaan 100
3584 CX Utrecht
Nederland
Listed location countries
Age
Inclusion criteria
Patients with a history of thrombotic thrombocytopenic purpura. Patients are approched by the
Exclusion criteria
None
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL13794.041.06 |